Brainsway Ltd.

Brainsway™ is a leading provider of technology for brain disorder treatment.  Established in 2003, Brainsway went public in January 2007 and is traded in the Tel Aviv Stock Exchange (TASE: BRIN). Brainsway is dedicated to innovation and runs clinical research programs with leading scientists around the world, collaborating with prominent institutions and researchers in clinical trials.

Brainsway Deep TMS

Brainsway's flagship technology is Deep TMS, or Deep Transcranial Magnetic Stimulation, which has created an entirely new and promising avenue for helping brain disorder patients. Deep TMS is an effective, non-invasive, non-drug treatment, which uses directed electromagnetic fields to generate excitation or inhibition of neurons deep inside the brain.

FDA Cleared for Depression Treatment

Brainsway's Deep TMS is FDA cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288). The FDA indication was issued following a 16-week double-blind, placebo-controlled, multi-center study* which enrolled over 200 subjects, and reported a marked decline in HDRS-21 scores, as well as significant remission (32.6%) and response (38.4%) rates at the primary endpoint of the study after 4 weeks of acute treatment. In the study, Brainsway's treatment was proved to be safe, and the treatment was well tolerated by the majority of the study subjects.

CE Cleared for Various Brain Disorders

Deep TMS is also CE cleared for treating a variety of disorders, including:

  • Alzheimer's disease
  • Autism
  • Bipolar disorder
  • Chronic pain
  • Major depressive disorder
  • Parkinson's disease
  • Posttraumatic stress disorder (PTSD)
  • Schizophrenia (negative symptoms)
  • Stroke rehabilitation
  • MSC (Multiple Sclerosis)
  • OCD (Obsessive Compulsive Disorder)
  • Smoking cessation

Brainsway's Transcranial Magnetic Stimulation technology is based on patents filed by the U.S. National Institutes of Health (NIH), and by the company. 

Wide Range of Advantages for Patients

A major advantage of Deep TMS is that it does not have the systemic side effects associated with medication. While medication is linked to side effects such as weight gain, insomnia and sexual dysfunction, Deep TMS has not been shown to cause such conditions.

Furthermore, Deep TMS sessions are almost 50% shorter than other TMS sessions, which are typically 37 minutes long. Deep TMS requires only brief 20-minute sessions, 5 days a week, for 4-6 weeks. This treatment format allows Deep TMS to integrate naturally into the patient's life.

Deep TMS has been shown to be safe. It does not require hospitalization or anesthesia, and does not entail the risk of memory loss which is typical of ECT.

Deep Stimulation for Best Results

Studies have shown that the depth and wide range of brain stimulation have a substantial positive impact on the results, as follows:

“Many behavioral manifestations of neurological and psychiatric diseases are not solely the result of abnormality in one isolated brain region but represent alterations in brain networks and connectivity.” (Fox et al. Neurolmage 2012)

"Deeper (ventral) PFC structures have significantly more connections with other reward system sites compared to superficial PFC". (Leh et al., 2007)

“There is significant inter-individual variability in the exact location of DLPFC sites having functional connectivity with subgenual cingulate “(Fox et al. Neuroimage  2012)

“Effective response to standard TMS in MDD is strongly correlated with resting state functional connectivity between DLPFC stimulation sites and subgenual cingulate “(Fox et al. Biol. Psychiatry 2012).

“Individualized targeting becomes less important with larger stimulation field sizes” (Fox et al. Biol. Psychiatry 2012)

Optimized for Research

Brainsway Transcranial Magnetic Stimulation technology includes a double blind system which enables researchers to effectively hold randomized studies. It can stimulate a wide variety of brain regions and networks. It can easily be applied to diverse clinical applications by designing coils targeting different locations, depths, directionalities & morphologies relevant to target neuronal structures, and usage of different protocols during treatment.